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Abstract
Introduction: Genome-wide association studies (GWAS) for late onset Alzheimer’s disease (AD) may miss genetic variants relevant for delineating disease stages when using
clinically defined case/control as a phenotype due to its loose definition and heterogeneity.
Methods: We use a transfer learning technique to train three-dimensional convolutional neural network (CNN) models based on structural magnetic resonance imaging
(MRI) from the screening stage in the Alzheimer’s Disease Neuroimaging Initiative consortium to derive image features that reflect AD progression.
Results: CNN-derived image phenotypes are significantly associated with fasting
metabolites related to early lipid metabolic changes as well as insulin resistance and
with genetic variants mapped to candidate genes enriched for amyloid beta degradation, tau phosphorylation, calcium ion binding-dependent synaptic loss, APP-regulated
inflammation response, and insulin resistance.
Discussion: This is the first attempt to show that non-invasive MRI biomarkers are
linked to AD progression characteristics, reinforcing their use in early AD diagnosis and
monitoring.
KEYWORDS
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HIGHLIGHTS

RESEARCH IN CONTEXT

∙ Novel non-invasive magnetic resonance imaging (MRI)

1. Systematic review: Case/control genome-wide associa-

biomarkers of Alzheimer’s disease progression.

tion studies (GWAS) for late onset Alzheimer’s disease

∙ Transfer learning.
∙ Deep convolutional neural networks.

(AD) may miss genetic variants relevant for delineating disease stages because the cases highlight advanced
AD and widely heterogeneous mild cognitive impairment
patients are usually excluded. More precise phenotypes
for AD are in demand.

1

2. Interpretation: Convolutional neural networks (CNN)

BACKGROUND

trained on structural magnetic resonance imaging (MRI)
and clinical labels integrated AD classification and image

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder

feature extraction in one step; transfer learning–trained

that slowly degrades memory and cognitive functions. It is neu-

CNN were more robust to overfitting, yielding more accu-

ropathologically defined by intracellular neurofibrillary tangles and
aggregated amyloid beta (Aβ)

plaques,1

rate image features that predict AD progression. CNN-

both of which can currently

derived image phenotypes were significantly associated

be estimated accurately only post mortem. The phenotype in current

with metabolites related to early lipid metabolic changes

case/control genome-wide association studies (GWAS) for late onset

and insulin resistance, and with genetic variants mapped

AD (LOAD)2–4 are based largely on clinical assessments, in which

to candidate genes enriched for amyloid beta degrada-

mild cognitive impairment (MCI) and AD are determined by designed

tion, tau phosphorylation, calcium ion binding-dependent

memory and cognitive tests and clinical observations. These criteria

synaptic loss, APP-regulated inflammation response, and

fail to reflect early AD hallmark characteristics such as Aβ plaques and

insulin resistance.

neurofibrillary tangles and highlight advanced AD, leaving the MCI

3. Future direction: Relating the MRI biomarkers to specific

category widely heterogeneous and poorly understood. Consequently,

regions in original MRI images that drive the AD classifi-

current GWAS for LOAD usually exclude MCI and therefore may miss

cation.

critical genetic variants associated with early AD characteristics and
progression.
Non-invasive brain imaging modalities such as magnetic resonance
imaging (MRI) and positron emission tomography (PET) are promising

MCI. This is supported by the significant associations we find between

tools for monitoring AD progression and its diagnosis. Imaging pro-

the CNN-derived phenotypes and early AD-related metabolites and

vides precise quantitative phenotypes, and numerous methods have

genes (Figure 1). To our knowledge, this is the first attempt to link non-

been proposed for analyzing neuropathology with

MRI.5–9

However,

invasive MRI biomarkers with AD progression characteristics.

the high dimensionality of these phenotypes makes it challenging to
extract concise and interpretable information. Summary measures for
pre-defined regions of interest (ROI) are suboptimal for predicting the

2

METHODS

onset and progression of AD because they are derived independently
of AD status.
In this article, we make use of deep convolutional neural networks

2.1
MRI and clinically labeled data from the
ADNI consortium

(CNN)10–13 to simultaneously extract relevant features and classify
patients using (structural) MRI data from the Alzheimer’s Disease Neu-

Data for this study were obtained from the ADNI database

roimaging Initiative (ADNI) consortium. Deep CNN have become the

(adni.loni.usc.edu). ADNI is a longitudinal study in which initial

state-of-the-art methods for image classification14 due to their abil-

imaging is followed by annual reimaging. MRI images taken at the

ity to form translation invariant hierarchical image features. To miti-

initial stage are later categorized into four major classes based on their

gate the scarcity of images in the ADNI dataset, and accommodate the

follow-up status: control, AD, stable MCI subjects who maintain the

high number of model parameters that need to be learned, we adopt

same disease status throughout the follow-up period, and progressive

a transfer learning technique.15,16 This technique uses an indepen-

MCI subjects who convert from MCI to AD sometime during the

dent data-trained 3D CNN model17 that is then fine-tuned using our

follow-up period. MCI were counted as stable MCI only if they were

dataset of 1381 images. This greatly augments our image dataset and

followed-up for at least 3 years in this study. The conversion and

ensures the learned CNN model is more robust to overfitting. Because

follow-up timelines for the 526 MCI patients are shown in Table S1B in

our baseline MRI images were taken 3 years prior to clinical labeling

supporting information.

and provide holistic snapshots of brain states, our CNN-derived image

We downloaded 817 screening images from the ADNI-1 cohort,

features reflect earlier and more specific AD characteristics than the

104 ADNI-GO new participants, and 624 ADNI-2 new participants.

memory and cognitive performance features used for assessing AD and

Because AD patients rarely convert back, we included 162 Year 1
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APOE genotype and 4
cognitive scores

MRI

Age, four cognitive scores (Mini-Mental State Examination [MMSE],
Clinical Dementia Rating-Sum of Boxes [CDR-SOB], Functional Activities Questionnaire [FAQ], Alzheimer’s Disease Assessment Scale
[ADAS]), and various image summary measures at screening as well as
sex, education level, apolipoprotein E (APOE) genotype, and ethnicity
were downloaded. The subjects used for training CNN had MRIs and

Image CNN model

Augmented CNN model

all selected covariates, with only one subject missing cognitive score
examination date at screening. Most of the MRIs had examination date
within 2 months from that of cognitive scores (Table S1C). The distribu-

3 phenotypes: imageCNN.PC1,
imageCNN.PC4, imageCNN.PC9

tions of age, sex, MMSE, and APOE genotype are shown in Table 1.
1 phenotype: augmentedCNN.PC2

2.2
metabolite association, GWAS, FUMA gene mapping, AMP-AD
gene co-expression submodule enrichment analysis

CNN and feature formation

CNN is a type of supervised multiple-layer neural network that adopts
learnable convolutional kernels to detect hierarchical image features.
Because the same kernel slides over the whole image, the detected
image features are translation invariant.20 To reinforce this, input

Legend:

input

analysis

derived phenotypes

images are often augmented during CNN training via transformations
such as multiple scaling and cropping. A loss value at the last layer of

F I G U R E 1 Graphic summary of the analytical approach. AMP-AD,
Accelerating Medicines Partnership-Alzheimer’s Disease; APOE,
apolipoprotein E; CNN, convolutional neural network; GWAS,
genome-wide association studies; MRI, magnetic resonance imaging

a CNN is computed in the forward pass and iteratively minimized by
back-propagating the loss to all hidden layers to update their weights
based on the stochastic gradient descent rule.21
The pre-trained 3D CNN model used for the transfer learning
adopted ResNext101 network structure, which consists of 101 layers, and was trained using 300,000 Kinetics video clips.22 Only the

and 95 Year 2 images from ADNI-1 patients who were diagnosed

parameters in the last few layers of ResNext101 were fine-tuned dur-

as AD at screening, 155 of which also had MRIs at screening, total-

ing the training stage of our dataset. We added nodes to the second-

ing 1802 images (Table S1A). The adding of Year 1/2 AD images to

to-last layer in ResNext101 structure to accommodate covariates

screening images was expected to help CNN more accurately rec-

(Figure S1 in supporting information). Our preliminary classification

ognize progression-related image features. However, there were no

results showed that progressive MCI was frequently predicted as AD

duplicate subjects in the downstream metabolite and GWAS analy-

by the CNN model, suggesting that the CNN classification possibly

sis. Some subjects in ADNI-1 have two MRI scans from the same ses-

reclassified patients with pending diagnosis. We therefore trained our

sion; we kept the one in the “Scaled_2″ directory as recommended

CNN models with the target classes of controls, stable MCI, and broad

by ADNI MRI core team. We filtered out Year 1 to 2 AD MRIs with

AD (AD and progressive MCI).

the rank of 4 or -1 (based on downloaded MRIMPRANK.csv) and

To maximize the chance of obtaining an accurate CNN model,

ADNI-GO/2 MRIs with the quality of 4 or none (based on downloaded

we generated 10-fold sample splits. The three classes of subjects were

MAYOADIRL_MRI_IMAGEQC_12_08_15.csv). When there was more

evenly divided into 10 folds in a class-wise fashion; for each sample

than one MRI scan from the same session after filtering, we kept the

split, one fold was used as an independent test set, the remaining nine

one with the highest quality or the latest timepoint when qualities were

folds were randomly split into training and validation sets with the ratio

equal.

of 9:1. One CNN model was learned on the training and validation sets

FreeSurfer18,19 software (-autorecon1 option) was applied to cor-

in each of the 10 sample splits, and the one with the highest classifi-

rect motions, normalize image intensities, and strip bone tissue, fol-

cation accuracy on the (independent) test set was selected as the best

lowed by manual checking of sagittal slice 101 of each MRI image,

model for downstream analyses.

ensuring that the mean intensity of the white matter was around 110

The second-to-last layer of our CNN was the only layer that pro-

and skull was stripped correctly (FreeSurfer suggestions). Inappropri-

vided input for the class probabilities at the last layer, and therefore

ate skull stripping was rescued by running mri_watershed with dif-

contained the features that are the most predictive of the classification.

ferent watershed thresholds. MRIs with incorrect mean intensity of

This layer yielded 2048 image features in the adopted ResNext101

the white matter or inappropriate skull stripping after rescuing were

structure (Figure S1). Covariates entered CNN at this layer and their

excluded. To investigate whether co-registration is necessary when

effects were passed forward to compute the loss at the last layer, which

applying CNN to brain image analysis, we used the Talairach transfor-

was propagated backward to all the hidden layers including the second-

mation calculated in FreeSurfer (-autorecon1) to obtain MNI305 atlas-

to-last layer. Hence, when there are covariates in our CNN model,

registered MRIs.

the extracted image features are covariate adjusted. To reduce the
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TA B L E 1

Demographic assessment and APOE ε4 genotype distribution in ADNI and AIBL data
ADNI data

AIBL data
No. of APOE ε4 copies

No. of
subjects

Age

Male/female

0

1

Control

373

74.3 ± 6

182/191

274

91

AD

251

74.8 ± 8

134/117

84

No. of APOE ε4 copies

2

No. of
subjects

Age

Male/female

0

1

2

MMSE

9

107

70.8 ± 7

51/56

76

30

1

29.1 ± 1.1

114

53

74

73.2 ± 8

29/45

23

37

14

20.3 ± 5.6

sMCI

424

73.1 ± 8

255/169

246

141

37

10

77.2 ± 7

8/2

5

4

1

28.0 ± 1.5

pMCI

230

73.9 ± 7

134/96

77

114

39

11

74.9 ± 6

7/4

1

6

4

26.3 ± 1.7

0.047

0.26

5.72 × 10

–30

0.28

0.26

4.51 × 10

–10

0.72

0.64

3.21 × 10–09

0.25

0.43

0.033

P-Value

1

P-Value2

2.93 × 10–16
0.18

Notes: Age is presented in a mean ± standard deviation format.
ADNI, sMCI, and pMCI were estimated until 3 years from screening (for CNN training); AIBL, sMCI, and pMCI were estimated until 6 years from baseline (for
CNN evaluation).
P-value1 : P value of comparing AD and controls.
P-value2 : P value of comparing sMCI and pMCI.
Abbreviations: AD, Alzheimer’s disease; ADNI, Alzheimer’s Disease Neuroimaging Initiative; AIBL, Australian Imaging, Biomarker & Lifestyle Flagship Study
of Ageing; APOE, apolipoprotein E; MMSE, Mini-Mental State Examination; pMCI, progressive MCI; sMCI, stable MCI.

number of image features for downstream analyses, we applied prin-

as ADNI MRIs. Participants’ characteristics were described in Dang

cipal component analysis (PCA)23 to the 2048 image features, used the

et al.26 and Ellis et al.27 Age, sex, APOE ε4 genotype, and MMSE are

broken stick model24

to estimate the number of PCs needed, followed

summarized in Table 1 and used here as covariates. Education level and

by a L1 -norm regularized regression model (Lasso25 ) to select the most

cognitive scores of ADAS and FAQ, not available to our access, were

informative PCs for distinguishing stable and progressive MCIs. These

assigned values of zero to remove their effects in our CNNs. CDR was

PCs are hereafter referred to as CNN-derived image phenotypes. After

available and used here instead of CDR-SOB. Youden’s J statistics24

CNN was trained, covariates were not needed to obtain the image phe-

was applied to the class probabilities of CNN to determine the pre-

notypes, but needed for disease status predictions.

dicted class category.

We generated two sets of CNN-derived phenotypes. For the first,
we trained a CNN model with age at screening, sex, education level,
MRI field strength indicator (1.5T or 3T), and ethnicity as covariates

3

RESULTS

(hereafter Image CNN). For the second set, we included APOE genotype
as an additional covariate, along with four APOE-correlated cognitive
scores at screening (hereafter Augmented CNN model).

3.1
Deep 3D CNN models classify transition
from MCI to AD accurately

To evaluate the performance of our CNN-derived image phenotypes, we correlated them with metabolites and genetic variants. We

The confusion matrices for the best CNN models on unregistered MRIs

also compared them with conventional image summary measures, cog-

are shown in Table 2. The Augmented CNN yielded prediction accuracy

nitive scores, and clinical labels. See supporting information for addi-

of 0.992 for broad AD, 0.986 for controls, and between 0.911 (1-year

tional details.

follow-up) to 0.801 (the final visit) for progressive MCI. In comparison, the Image CNN achieved prediction accuracy of 0.913 for broad
AD, 0.906 for controls, and between 0.822 (1-year follow-up) to 0.69

2.3

AIBL MRIs as a validation dataset

(the final visit) for progressive MCI. The Image CNN had lower power to
differentiate stable MCI from healthy controls. Both models had lower

We used MR images from the Australian Imaging, Biomarker &

error rate of predicting stable MCI as broad AD with longer follow-up

Lifestyle Flagship Study of Ageing (AIBL) to evaluate the performance

period (0.409 to 0.192 for Augmented CNN, 0.376 to 0.2 for Image CNN),

of the trained CNNs. AIBL, designed similarly to ADNI, is a longitudi-

implying that some of the stable MCI that were predicted by CNN as

nal study that follows-up participants every 18 months until 6 years

broad AD converted to AD when tracked for longer than 3 years. We

from screening. All subjects were assumed to be White, a subset of

also trained the two CNN models using co-registered MRIs. As shown

whose MRIs were provided at the ADNI website. We selected 207 sub-

in Figure 2A and B, CNN performance on non-registered and regis-

jects who had one MRI scan at baseline and either remained as con-

tered MRIs was not significantly different, verifying that CNN is able to

trols/MCI/AD for at least 3 years or converted to AD during the 6-

learn translation-invariant image features. However, Image CNN with

year follow-up. There were only 10 stable MCI and 11 progressive MCI

the same structure had a bigger performance difference between train-

among 207 subjects. The MRIs, 60 of which were of 1.5T magnetic

ing and test samples on registered MRI than on non-registered MRI

strength and 147 of 3T, went through the same pre-processing step

(Figure 2C), implying that Image CNN might be somewhat overfitting for
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TA B L E 2

Confusion matrix for CNN predictions

Clinical label

Image CNN (trained without APOE genotype and cognitive
score as covariates)

Augmented CNN (trained with APOE genotype and
cognitive score as covariates)

Control

Control

Stable MCI

Broad AD

Stable MCI

Broad AD

3Y_ctrl (373)

0.895 (334)

0.0107 (4)

0.0938 (35)

0.96 (358)

0.0268 (10)

0.0134 (5)

AD (482)

0.0851 (41)

0.00207 (1)

0.913 (440)

0 (0)

0.0083 (4)

0.992 (478)

1Y_sMCI (425)

0.442 (188)

0.181 (77)

0.376 (160)

0.231 (98)

0.36 (153)

0.409 (174)

2Y_sMCI (336)

0.518 (174)

0.226 (76)

0.256 (86)

0.277 (93)

0.435 (146)

0.289 (97)

3Y_sMCI (296)

0.551 (163)

0.24 (71)

0.209 (62)

0.297 (88)

0.476 (141)

0.226 (67)

4Y_sMCI (278)

0.558 (155)

0.241 (67)

0.201 (56)

0.317 (88)

0.478 (133)

0.205 (57)

5Y_sMCI (271)

0.561 (152)

0.232 (63)

0.207 (56)

0.325 (88)

0.48 (130)

0.196 (53)

final_sMCI (255)

0.557 (142)

0.243 (62)

0.2 (51)

0.318 (81)

0.49 (125)

0.192 (49)

1Y_pMCI (101)

0.178 (18)

0 (0)

0.822 (83)

0.0198 (2)

0.0693 (7)

0.911 (92)

2Y_pMCI (190)

0.195 (37)

0.00526 (1)

0.8 (152)

0.0368 (7)

0.0737 (14)

0.889 (169)

3Y_pMCI (230)

0.209 (48)

0.0087 (2)

0.783 (180)

0.0522 (12)

0.0826 (19)

0.865 (199)

4Y_pMCI (248)

0.226 (56)

0.0403 (10)

0.734 (182)

0.0484 (12)

0.109 (27)

0.843 (209)

5Y_pMCI (255)

0.231 (59)

0.0549 (14)

0.714 (182)

0.0471 (12)

0.118 (30)

0.835 (213)

final_pMCI (271)

0.255 (69)

0.0554 (15)

0.69 (187)

0.0701 (19)

0.129 (35)

0.801 (217)

Notes: Number of samples is given in parentheses. The fraction at each entry stands for the ratio of the number of CNN predictions belonging to the column
category to the number of samples belonging to the row (clinical) category. That pMCI or AD were predicted as broad AD, and control/sMCI were predicted
as non broad AD can be viewed as correct predictions in a broad sense.
Abbreviations: AD, Alzheimer’s disease; ADNI, Alzheimer’s Disease Neuroimaging Initiative; APOE, apolipoprotein E; CNN, convolutional neural network;
pMCI, progressive MCI; sMCI, stable MCI.

registered MRI. This is probably because the transferred pre-trained

variance of the 2048 CNN-derived image features, respectively. Only

CNN was trained on non-registered images. Hence, all the downstream

PC 2 (hereafter augmentedCNN.PC2) was selected from Augmented

analyses are based on non-registered MRIs.

CNN model, explaining 0.064 of the variance of the 2048 image features. Only imageCNN.PC4 and augmentedCNN.PC2 had a high cor-

3.2

Trained CNNs applied to AIBL MRIs

relation coefficient of 0.72; all other pairwise correlations of PCs were
below 0.3.

CNN analysis was also informative in our AIBL validation dataset, especially for Image CNN as the relevant cognitive data were not available
for Augmented CNN. Area under the curve (AUC) of distinguishing controls from AD was 0.78 for Image CNN and 0.76 for Augmented CNN.
AUC of differentiating stable and progressive MCI were lower—0.61
and 0.6, respectively (Table S3 in supporting information)—probably
due to the smaller sample size (21 subjects total). The Augmented CNN
performed worse than the Image CNN, probably because ADAS, FAQ
and CDR-SOB were not available. Potential reasons for the reduced
AUC compared to ADNI analysis include (1) MRI acquisitions in ADNI
and AIBL used slightly different protocols and (2) some overfitting in
the trained CNN in spite of the transfer learning, as the trained CNN
was fitted to a North American population whereas AIBL data were
drawn from Australia.

3.4
Image phenotypes are associated with early
AD-related metabolites
Seven metabolites were found to be significantly (P < 0.05/55 =
0.0009) associated with the four CNN-derived phenotypes in the
ADNI-1 participants (Table S4 in supporting information), including
two phosphatidylcholines (PC) metabolites (PC ae C44:4 associated
with imageCNN.PC1, PC aa C32:3 with augmentedCNN.PC2), and
three sphingomyelin (SM) metabolites (SM C16:1, SM C18:0, and SM
C20:2, with augmentedCNN.PC2). These PC or SM metabolites were
previously found to be significantly associated with cerebrospinal fluid
(CSF) Aβ 1-42 and/or CSF tau in ADNI-1 cohort, either directly or
indirectly.28 Significant branched-chain amino acids included histidine
(with imageCNN.PC9) and isoleucine (with augmentedCNN.PC2), both

3.3

Image phenotypes derived from 3D CNNs

of which have been previously implicated in insulin resistance.28,29 We
need to caution the reader that the interpretation may be overstated as

Using Lasso,25 we selected principal components 1, 4, and 9 as infor-

the metabolite association was performed only in ADNI-1 participants

mative phenotypes from Image CNN model (hereafter imageCNN.PC1,

while image-derived phenotypes were obtained from ADNI-1/GO/2

imageCNN.PC4, imageCNN.PC9), explaining 0.257, 0.035, 0.019 of the

participants.
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F I G U R E 2 Average AUC (area under the receiver operating characteristic curve) of predicting stable and progressive mild cognitive
impairment (MCI) among 10 sample splits for six follow-up periods, comparing registered and non-registered images. A, Image CNN model on test
samples (with error bar). B, Augmented CNN model on test samples (with error bar). C, Comparison of average AUC between training and test
samples. CNN, convolutional neural network; pMCI, progressive mild cognitive impairment; sMCI, stable mild cognitive impairment

7 of 11

LI ET AL .

3.5

GWAS using CNN-derived image phenotypes

a role in synaptic plasticity.32 NCAM2 mediates synaptic adhesion, and
Aβ-dependent disruption of NCAM2 functions in the AD hippocampus

The results for meta GWAS on imputed SNPs (see supporting infor-

contributes to synapse loss.33 BRSK1 is the eQTL target gene of signif-

mation) using the four CNN-derived image phenotypes are shown in

icant rs429498 in the AMP-AD RNA-Seq data, and mediates phospho-

Table 3 and Table S5 in supporting information. QQ plots for all phe-

rylation of tau.34 Therefore, we believe that Image CNN detected image

notypes show no obvious inflation of large P-values (> 1 ×

patterns that are related to calcium ion binding, Aβ-mediated synaptic

10–4 ),

with

λGC between 0.993 and 1.01, indicating that our association analyses

loss, and tau phosphorylation.
For Augmented CNN, CDH13 negatively regulates axon growth35 and

have accounted for population substructure well (Figure S2 in support-

LMF1 is required for maturation and transport of active lipoprotein

ing information).
Using imageCNN.PC1 as a phenotype, we obtained genomewide significant P-values (<5 ×

10–8 )

lipase (LPL).36 Previous studies have established that LPL is a novel Aβ-

for genetic variants at the

binding protein promoting cellular uptake and subsequent degradation

APOE/TOMM40 locus (Figure S2A). However, its QQ plot shows

of Aβ.37 ENSA is an inhibitor of protein phosphatase 2A (PP2A)38 that

no upward deviation from the diagonal line when single nucleotide

regulates tau phosphorylation directly. ADCY3 loss-of-function vari-

polymorphisms (SNPs) at the APOE/TOMM40 locus are excluded

ants increase the risk of obesity and type 2 diabetes.39 ZC3H12A (a.k.a.

(Figure S2B), suggesting that imageCNN.PC1 is not significantly asso-

MCPIP1), detected by both CNN models, is an APP-regulated inflam-

ciated with any genetic variants outside APOE given the current

mation respondent in NT2 cells.40 All together, we believe that aug-

sample size. In contrast, using imageCNN.PC4, imageCNN.PC9, and

mentedCNN.PC2 represented both early (Aβ and tau related) and late

augmentedCNN.PC2 as phenotypes revealed no significant variants at

(insulin resistance/diabetes and inflammation response) AD character-

the APOE/TOMM40 locus (P < 1 × 10–5 ). Their QQ plots show moderate

istics.

excess of low P-values even when SNPs at the APOE/TOMM40 locus are
excluded (Figure S2C-2E), suggesting that these phenotypes are significantly associated with variants outside APOE given the current sample

4

DISCUSSION

size.
GWAS based on imageCNN.PC4 and imageCNN.PC9 identified 116

Augmented CNN model achieves higher prediction accuracy than Image

and 41 significant (P < 1 × 10–5 ) SNPs, respectively (Figure 3A), which

CNN model in the ADNI cohort. The high accuracy achieved by both

were mapped to 17 protein-coding genes (within ±15 kb) according to

models, as well as the four cognitive scores and APOE genotype, for dis-

Identified SLC24A4 (rs12588868, P = 9.07 × 10–6 ) is a known

tinguishing stable and progressive MCI (Table S2 in supporting infor-

FUMA.30
AD

gene;4

two genes, CACNA1C (rs11062078, P = 3.14 ×

10–6 )

and

DYSF (rs34707417, P = 6.38 × 10–6 ), were significantly enriched in the

mation) implies that image, cognitive performance, and genetics have
complementary roles in disease status prediction.

Accelerating Medicines Partnership-Alzheimer’s Disease (AMP-AD)

ImageCNN.PC1 is the only CNN-derived phenotype to identify

gene co-expression submodules (Figure S3 in supporting information).

genome-wide significant SNPs at the APOE locus because principal

The Gene Ontology (GO) annotations for the enriched submodules

components are uncorrelated with one another by definition and Aug-

include regulation of action potential and calcium-mediated signaling

mented CNN-derived image features were APOE-adjusted. This pheno-

for CACNA1C and regulation of endocytosis for DYSF (Table S7 in sup-

type also had the highest power (AUC = 0.784) to predict the clini-

porting information). DYSF has been reported to be significantly asso-

cal conversion of MCI to AD among all the phenotypes we considered

ciated (P < 1 × 10–4 ) with AD in an exome array association study.31

(Table S2), and the highest Pearson correlation with cognitive scores

AugmentedCNN.PC2 identified 130 SNPs with P-values < 1 ×

(0.55 with ADAS and 0.52 with CDR-SOB). However, its QQ plot shows

10–5 (Figure 3B), which were mapped to 12 protein-coding genes

no excess of low P-values outside of the APOE locus. We therefore

(within ±15 kb) according to FUMA. Two genes, CDH13 (rs67805160,

believe that imageCNN.PC1 represents image features that are mainly

P = 4.26 ×

redundant with APOE genotype and cognitive performance.

10–6 )

and ENSA (rs112175941, P = 2.48 ×

10–6 )

were sig-

nificantly enriched in AMP-AD gene co-expression submodules (Fig-

The other three CNN-derived phenotypes show low correlations

ure S3), whose GO annotations include calcium-dependent cell–cell

with cognitive scores (<0.1) and have relatively low power to predict

adhesion for CDH13, negative regulation of dephosphorylation, and

the clinical conversion of MCI to AD (Table S2). This is probably due

regulation of hormone/insulin secretion for ENSA (Table S8 in support-

to the conversion assessment being largely based on cognitive perfor-

ing information).

mance in the first place. However, these phenotypes are associated
with early-stage markers of disease. For example, augmentedCNN.PC2
is significantly associated with the largest number of lipid metabolites

3.6
Candidate genes link image phenotypes
to AD-related functions

(three sphingomyelin and one phosphatidylcholines; Table S4), which
have been previously found significantly associated with CSF Aβ 1-42
and/or CSF tau.28 Furthermore, imageCNN.PC9 is significantly asso-

For Image CNN, three candidate genes (SLC24A4, CACNA1C, DYSF) are

ciated with a metabolite of histidine, which has been implicated in

related to the GO term of calcium ion binding, which may in turn play

insulin resistance and p-tau.29,41 Their most significant SNPs map to
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F I G U R E 3 Manhattan plots for (A) principal components (PCs) 1, 4, and 9 of the Image CNN-derived image features, and (B) PC 2 of the
Augmented CNN-derived image features. Gene names in red text are for imageCNN.PC1, those in blue text are for imageCNN.PC4,
imageCNN.PC9, and augmentedCNN.PC2

protein-coding genes that are enriched for diverse AD stages, rang-

gorical clinical labels are more prone to errors due to the use of thresh-

ing from early Aβ, tau phosphorylation, and calcium ion binding-

olds than the continuous CNN-derived image phenotypes.42

related synaptic loss to late energy hypo-utilization and inflammation

Although we have applied FreeSurfer to the downloaded pre-

response. Moreover, our CNN-derived phenotypes compare favorably

processed MRI images to correct motion and normalize image inten-

to other AD-related phenotypes (cognitive scores, image summary

sities, we acknowledge that some confounding effects may not have

measures, and clinical labels) in terms of metabolite association and

been accounted for, due to the different MRI acquisition parameters

GWAS findings (Table S4 and S6 in supporting information). Although

adopted at different sites. This could also explain the lower prediction

the CNN-derived image phenotypes could be explained to some degree

power in the independent AIBL MRIs.

by a linear combination of image summary measures from ROIs—with

One direction for future studies is to explore CNN training strate-

the highest explaining R2 of 0.358 for imageCNN.PC1 (Figure S4A in

gies that can better tolerate inaccurate target labels; another one is to

supporting information), followed by the explaining R2 of 0.133 for

identify the regions in the original MRI images that drive the CNN clas-

augmentedCNN.PC2 (Figure S4B) the majority of the image pheno-

sification.

types were unexplained by the ROIs, showing that the CNN-derived
image phenotypes provide novel MRI biomarkers.
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